In honor of Acute Myeloid Leukemia (AML) Awareness Day, Oncology Data Advisor Editorial Board and Fellows Forum members Tristan Knight, MD, FRCPC, Richa Thakur, MD, and Joseph Kalis, PharmD, BCOP, hosted a live panel discussion covering the evolving treatment landscape for AML, including:
• Novel therapies and combinations such as chimeric antigen receptor (CAR) T-cell therapy and isocitrate dehydrogenase (IDH) inhibitors
• The role of measurable residual disease (MRD) testing
• Considerations for pediatric transplant and cellular therapy
• Words of hope for patients undergoing treatment for AML
Additionally, they answered live questions from the audience, including:
• Do you have any first-line treatment recommendations for patients with a KMT2A mutation?
• When do recommend that patients participate in a clinical trial?
Take a listen to hear the panelists’ answers to these questions and their perspectives on the ever-changing therapeutic landscape for AML!
